TheraGenetics Bought by Avacta

Luke Timmerman1/29/09

TheraGenetics, a Cambridge, MA and London-based diagnostics company, said today it agreed to be acquired by UK-based Avacta Group for an undisclosed amount of cash and stock. TheraGenetics is developing diagnostic tests to see how individual patients might respond to drugs for schizophrenia, depression, bipolar disorder, Alzheimer’s disease and attention deficit hyperactivity disorder.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @